Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 8 art units • 12 examiners • 0 of 16 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Daiichi Sankyo Company, Limited maintains a robust prosecution pipeline with 16 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 12 distinct examiners across 8 distinct art units. The distribution indicates a diverse set of active applications requiring coordination across multiple specialized patent office divisions. With 8 distinct art units involved, the portfolio covers a wide range of specific sub-technologies within the broader pharmaceutical sector.
ANTHOPOLOS, PETER serves as the busiest examiner for this portfolio, managing 2 pending office actions. This concentration is relatively low given the total of 16 pending actions, as the other actions are spread among the 12 distinct examiners. The company is engaging with a broad cross-section of the patent office's expertise. This decentralized approach to the pending office actions may require a more varied strategy for responses compared to portfolios concentrated under fewer examiners.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (44%) |
| Double-patenting + other | 5 (31%) |
| Multi-statute (no §101) | 4 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANTHOPOLOS, PETER | 2 | 57.4% | +58.8% |
| GALSTER, SAMUEL LEONARD | 2 | 50.9% | +43.2% |
| CANELLA, KAREN A | 2 | 62.2% | +32.8% |
| SKOKO III, JOHN JOSEPH | 2 | 53.1% | +58.2% |
| LIU, TRACY | 1 | 54.5% | +27.3% |
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
| PETRASH, HILARY ANN | 1 | 64.5% | +51.7% |
| PAK, YONG D | 1 | 74.6% | +14.3% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| KNIGHT, SAMANTHA JO | 1 | 31.3% | +73.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | SKOKO III, JOHN JOSEPH | 71d overdue |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 6d |
| 18561804 | HPV INFECTIOUS DISEASE VACCINE | ANTHOPOLOS, PETER | 46d |
| 18562059 | HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE | ANTHOPOLOS, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | SKOKO III, JOHN JOSEPH | 71d overdue |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | TATGE, LEXUS MARC | 36d overdue |
| 17787760 | FILM-COATED TABLETS HAVING SMOOTH SURFACE | KNIGHT, SAMANTHA JO | 32d overdue |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 6d |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | GALSTER, SAMUEL LEONARD | 22d |
| 18561804 | HPV INFECTIOUS DISEASE VACCINE | ANTHOPOLOS, PETER | 46d |
| 17312084 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH PARP INHIBITOR | SKOKO III, JOHN JOSEPH | 54d |
| 18708875 | PHARMACEUTICAL COMPOSITION HAVING EXCELLENT DISSOLUTION PROPERTIES | LIU, TRACY | 62d |
| Art Unit | Apps |
|---|---|
| 1643 | 5 |
| 1614 | 2 |
| 1693 | 2 |
| 1641 | 2 |
| 1611 | 1 |
| 1637 | 1 |
| 1644 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708875 | PHARMACEUTICAL COMPOSITION HAVING EXCELLENT DISSOLUTION PROPERTIES | LIU, TRACY | 1614 | §103 | Final Rejection | 62d | Pending | May 09, 2024 |
| 18561804 | HPV INFECTIOUS DISEASE VACCINE | ANTHOPOLOS, PETER | 1611 | §103§112Other | Non-Final OA | 46d | Pending | Nov 17, 2023 |
| 18562059 | HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE | ANTHOPOLOS, PETER | — | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 1693 | §103§112 | Non-Final OA | 6d | Pending | Jul 26, 2023 |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | TATGE, LEXUS MARC | 1637 | §103§112DP | Non-Final OA | 36d overdue | Pending | Jun 07, 2023 |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | GALSTER, SAMUEL LEONARD | 1693 | §103 | Final Rejection | 22d | Pending | May 12, 2023 |
| 18036290 | TREATMENT OF MESOTHELIOMA BY ADMINISTRATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE | CANELLA, KAREN A | 1643 | §103§112DP | Final Rejection | — | Pending | May 10, 2023 |
| 18036289 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY | PETRASH, HILARY ANN | 1644 | §102§103§112DP | Non-Final OA | — | Pending | May 10, 2023 |
| 18024258 | NOVEL ENDO-ß-N-ACETYLGLUCOSAMINIDASE | PAK, YONG D | 1652 | §103 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | SKOKO III, JOHN JOSEPH | 1643 | §102§103§112 | Final Rejection | 71d overdue | Pending | Jan 18, 2023 |
| 18016308 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | HUYNH, PHUONG N | 1641 | §112DPOther | Non-Final OA | — | Pending | Jan 13, 2023 |
| 17787760 | FILM-COATED TABLETS HAVING SMOOTH SURFACE | KNIGHT, SAMANTHA JO | 1614 | §103Other | Final Rejection | 32d overdue | Pending | Jun 21, 2022 |
| 17458225 | METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE | CANELLA, KAREN A | 1643 | §103Other | Non-Final OA | — | Pending | Aug 26, 2021 |
| 17312084 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH PARP INHIBITOR | SKOKO III, JOHN JOSEPH | 1643 | §103Other | Final Rejection | 54d | Pending | Jun 09, 2021 |
| 17262590 | EFFECTIVE METHOD FOR MANUFACTURING ANTIBODY-DRUG CONJUGATE | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | 2d overdue | Pending | Jan 22, 2021 |
| 16640914 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | KIM, YUNSOO | 1641 | §103DP | Final Rejection | 81d overdue | Pending | Feb 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial